Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission

International Journal of Hematology

Volumn 66, Issue 3, 1997, Pages 297-301

  Harada, Mine ^a   Akashi, Koichi ^b   Hayashi, Shin ^b   Eto, Tetsuya ^b   Takamatsu, Yasushi ^b   Teshima, Takanori ^b   Hirota, Yuichi ^b   Taniguchi, Shuichi ^b   Nagafuji, Koji ^b   Mizuno, Shinichi ^b   Gondo, Hisashi ^b   Niho, Yoshiyuki ^b  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NONE

Author keywords

Acute myelogenous leukemia; Autologous blood cell transplantation; G CSF priming

Indexed keywords

BUSULFAN; CYTARABINE; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER SURVIVAL; CELL TRANSPLANTATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 0031257473     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(97)00037-6     Document Type: Article

References (11)

1. Korbling M., Fliedner T.M., Holle R., Magrin S., Baumann M., Holdermann E. Autologous blood stem cell transplantation (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: Influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant. 7:1991;343-349.
2. Juttner CA. Blood stem cell transplants in acute leukemia. In: Gale RP, Juttner CA, Henon P, editors. Blood Stem Cell Transplants. Cambridge: Cambridge University Press, 1994:101-116.
3. Shimoda K., Okamura S., Harada N.et al. Granulocyte colony-stimulating factor receptors on human acute leukemia: Biphenotypic leukemic cells possess granulocyte colony-stimulating factor receptors. Cancer Res. 52:1992;3052-3055.
4. Miyauchi J., Kelleher C.A., Wang C., Minkin S., McCulloch E.A. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood. 73:1989;1272-1278.
5. Takamatsu Y., Teshima T., Akashi K., Inaba S., Harada M., Niho Y. Successful second autologous blood stem cell transplantation after G-CSF-combined conditioning for the treatment of high-risk acute myelogenous leukemia. Bone Marrow Transplant. 13:1994;325-327.
6. Teshima T., Harada M., Takamatsu Y.et al. Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of circulating haemopoietic stem cells. Br J Haematol. 84:1993;570-573.
7. Teshima T., Harada M., Takamatsu Y.et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant. 10:1992;215-220.
8. Minden M.D., Till J.E., McCulloch E.A. Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML). Blood. 52:1978;592-600.
9. Takahashi S., Okamoto S.I., Shirafuji N.et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant. 13:1994;239-245.
10. Bearman S.I., Appelbaum F.R., Buckner C.D.et al. Regimen-related toxicity in patients undergoing bone marrow trans plantation. J Clin Oncol. 6:1988;1562-1569.
11. Tobinai K., Kohno A., Shimada Y.et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 23:1993;250-257.